Migrants in European countries who have multiple risk factors are more likely to get tested for HIV than those with fewer risk factors, a study of 2834 migrants in 10 European countries has found.
The study was presented at last week’s International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026) by Dr Haoyi Wang of Maastricht University in collaboration with the Mi-Health partnership, a European network of migrant health organisations.
In 2024, migrants accounted for 56% of all new diagnoses of HIV in the European Economic Area (the EU plus Iceland, Liechtenstein and Norway). Dr Wang said that migrants, especially recent arrivals, experience more difficulties in accessing HIV testing and prevention methods than other groups. Studies have found that about 30% of migrants living with HIV acquire HIV after migrating and that the risk in some groups is considerably greater.
One reason often given for high rates of HIV acquisition and low rates of PrEP use and testing is that migrants are “hard to reach”, both due to barriers in supply (e.g. lack of entitlement to healthcare, language barriers) and in demand (e.g. migrants thinking they have ‘left HIV behind’ and are at low risk in their host country).
The Mi-Health study was designed, firstly, to contact migrants and ask about their HIV testing history and, secondly, to examine whether specific characteristics and vulnerabilities, especially in combination, acted as barriers to or incentives to test.
For this study, community-based organisation partners conducted outreach HIV testing between September 2024 and October 2025, in Belgium, Cyprus, France, Germany, Greece, Ireland, Italy, Spain, Sweden and the UK.
In total, 2834 people took a rapid test. Of them 37 (1.3% or one in every 77 tests) was reactive and 32 of those were linked to care and got a confirmatory test. Dr Wang commented that, considering that the rapid tests were largely conducted in ‘pop up’ tents and outreach vans, and there were often “substantial social, linguistic, legal, and administrative barriers” to overcome, the study in itself proved that people described as ‘hard to reach’ can be moved along the care continuum.
Alongside the tests, data was gathered about participants’ testing history, and whether they knew about, had used, or were currently on PrEP. Eighty-seven per cent of testers (2464 people) supplied enough data for analysis, of whom 2176 (88% of survey respondents or 77% of all testers) were migrants. The number in each country ranged from 599 in Belgium to 30 in Ireland.
The researchers then sorted the 2464 people into categories, or rather combinations of categories. These were based on gender/orientation (four categories: man who has sex with men, trans person, heterosexual woman and heterosexual man); migrant status (also four categories: documented/settled, refugee, asylum seeker and undocumented); engaged in sex work (two categorises, yes or no); and injecting drug use (also yes or no). This meant there were 64 possible combinations of status people could have.
Participants were further categorised on the basis of duration of residence, region of origin, and whether or not their host country had a national HIV policy that prioritised testing and prevention for migrants.
Including 288 people who were not migrants, 47% were heterosexual men, 34% heterosexual women, 14% gay and bisexual men and 6% trans and non-binary people. Eight per cent were sex workers and 6% people who injected drugs. Excluding the non-migrants, 54.5% were migrants who had citizenship, leave to remain or had a long-term visa, 7.4% were refugees, 23.4% were asylum seekers and 14.7% were undocumented.
(Note: though regulations differ by country, the difference between the last three categories is that refugees have had their status as people running from danger accepted, asylum seekers are applying for this status, and undocumented migrants have not yet applied, have had their application refused or are otherwise not in the system.)